{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:12:53Z","timestamp":1761894773999,"version":"3.33.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1136\/ard.2007.078915","type":"journal-article","created":{"date-parts":[[2008,8,12]],"date-time":"2008-08-12T17:35:09Z","timestamp":1218562509000},"page":"1352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy of rituximab in Felty\u00e2\u20ac\u2122s syndrome"],"prefix":"10.1016","volume":"67","author":[{"given":"V","family":"Lekharaju","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2007.078915_bib1","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1002\/art.10497","article-title":"Autoantibodies against granulocyte colony-stimulating factor in Felty\u00e2\u20ac\u2122s syndrome and neutropenic systemic lupus erythematosus.","volume":"46","author":"Hellmich","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.078915_bib2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0268-960X(96)90024-7","article-title":"Treatment of the neutropenia of Felty syndrome.","volume":"10","author":"Rashba","year":"1996","journal-title":"Blood Rev"},{"key":"10.1136\/ard.2007.078915_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/qjmed\/91.1.49","article-title":"Treatment of Felty syndrome with haematopetic growth factor granulocyte colony stimulating factor (G-CSF).","volume":"91","author":"Stanworth","year":"1998","journal-title":"QJM"},{"key":"10.1136\/ard.2007.078915_bib4","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/art.10947","article-title":"Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy.","volume":"48","author":"Silverman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.078915_bib5","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1177\/0091270007305297","article-title":"Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response.","volume":"47","author":"Breedveld","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1136\/ard.2007.078915_bib6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.berh.2004.05.002","article-title":"Felty\u00e2\u20ac\u2122s syndrome.","volume":"18","author":"Balint","year":"2004","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1136\/ard.2007.078915_bib7","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/ard.2004.025643","article-title":"Lack of efficacy of rituximab in Felty\u00e2\u20ac\u2122s syndrome.","volume":"64","author":"Sordet","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.078915_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/01.rhu.0000200326.17729.76","article-title":"Benefical response to Rituximab in refractory Felty\u00e2\u20ac\u2122s syndrome.","volume":"12","author":"Weinreb","year":"2006","journal-title":"J Clin Rheumatology"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724386169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724386169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2007.078915","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T07:41:30Z","timestamp":1737358890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724386169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S0003496724386169"],"URL":"https:\/\/doi.org\/10.1136\/ard.2007.078915","relation":{},"ISSN":["0003-4967"],"issn-type":[{"type":"print","value":"0003-4967"}],"subject":[],"published":{"date-parts":[[2008,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of rituximab in Felty\u00e2\u20ac\u2122s syndrome","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2007.078915","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 2008 Published by Elsevier Inc. Publishing Group and European League Against Rheumatism. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}